Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Oncology"

704 News Found

Merck completes acquisition of Harpoon Therapeutics
News | March 12, 2024

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager


Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Diagnostic Center | March 12, 2024

Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL

Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS


EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
Drug Approval | March 07, 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process


Pfizer joins hands with NIPER (Ahmedabad) to support Healthcare Innovation in India
Startup | February 27, 2024

Pfizer joins hands with NIPER (Ahmedabad) to support Healthcare Innovation in India

Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


Modi lays foundation stone of AIIMS Rewari in Haryana
News | February 17, 2024

Modi lays foundation stone of AIIMS Rewari in Haryana

AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block


Ascentage Pharma’s Phase III study of Olverembatinib cleared by FDA
Drug Approval | February 14, 2024

Ascentage Pharma’s Phase III study of Olverembatinib cleared by FDA

The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.


Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
News | February 10, 2024

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024


Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
News | February 10, 2024

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis


Zydus Lifesciences Q3 FY24 PAT up 26.8%
News | February 10, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.